GRPEL2

Across TCGA pan-cancer cohorts, GRPEL2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GRPEL2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GRPEL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GRPEL2 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where GRPEL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRPEL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.839	<.001	8	view →
LSCC	All	III,IV	+0.603	<.001	7	view →
HNSC	All	All	−0.342	.001	6	view →
CCRCC	All	III,IV	+0.283	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GRPEL2–LUAD

Open the LUAD breakdown →